IO Biotech to Present at the Jefferies Healthcare Conference
Get Alerts IOBT Hot Sheet
Join SI Premium – FREE
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy Sullivan, the company’s CFO, will be presenting and participating in one-on-one investor meetings at the Jefferies Healthcare Conference to be held June 7-9 in New York City.
Presentation DetailsDate and Time: Wednesday, June 7, 2023 12:30-12:55 PM ESTPresenter: Mai-Britt Zocca, Ph.D., President & CEOWebcast Link: https://wsw.com/webcast/jeff281/iobt/1850420
A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 90 days.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform. The T-win platform is a novel approach to cancer vaccines designed to activate T cells to target the most important immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing in clinical studies its lead cancer vaccine candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials and results, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:Maryann Cimino, Director of Investor RelationsIO Biotech, Inc.617-710-7305[email protected]
Investor Contact:Corey Davis, Ph.D.LifeSci Advisors212-915-2577 [email protected]
Source: IO BiotechSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Groupe Casino: BUT, Conforama, MDA Company, Casino Group and Intermarché end their technical goods purchasing partnership, Sirius Achats
- ACNB Corporation Announces Second Quarter Cash Dividend
- KOIL Energy Secures Major Contract
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!